NCI 10H03 (Protocol 8611): A Single-Arm Phase II Clinical Trial with the Novel MEK Inhibitor AZD-6244 hydrogen sulfate for the Treatment of MCT-1 Related Relapsed or Refractory Diffuse Large B-cell Lymphoma: Subproject for Institution # SP0012448

Project: Research project

Project Details

StatusFinished
Effective start/end date9/30/12 → 9/22/16

Funding

  • The University of Chicago (5-27050 / HHSN261201100071C)
  • National Cancer Institute (5-27050 / HHSN261201100071C)